Targeting MDM2 for novel molecular therapy: Beyond oncology

Area of Science:

• Oncology
• Molecular Biology
• Pathology

Background:

• The murine double minute 2 (MDM2) oncogene is a critical regulator of the p53 tumor suppressor and has p53-independent functions.
• MDM2 plays significant roles in human cancers, driving interest in targeted therapies.
• Emerging evidence highlights MDM2's involvement in various nonmalignant chronic diseases.

Purpose of the Study:

• To review recent findings on MDM2's role in the pathogenesis of nonmalignant diseases.
• To explore the therapeutic potential of MDM2 downregulation or inhibition in these conditions.
• To discuss the utility of MDM2 as a biomarker for diagnosis and treatment monitoring.

Main Methods:

• Literature review of preclinical and clinical studies.
• Analysis of research on MDM2's molecular mechanisms in disease.
• Synthesis of data on MDM2 inhibitors' efficacy and biomarker potential.

Main Results:

• MDM2 is implicated in inflammation, autoimmune diseases, neurodegeneration, cardiovascular conditions, nephropathy, diabetes, obesity, and sterility.
• MDM2 inhibitors demonstrate therapeutic efficacy in preclinical models of inflammation and other nonmalignant diseases.
• Understanding MDM2's function in nonmalignant diseases may yield novel diagnostic and prognostic biomarkers.

Conclusions:

• Targeting MDM2 presents a promising therapeutic strategy for both cancer and a range of nonmalignant chronic diseases.
• MDM2 inhibition offers potential for treating conditions like inflammation and cardiovascular diseases.
• MDM2 could serve as a valuable biomarker for diagnosing, predicting, and monitoring nonmalignant diseases.